- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07616206
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems (Hybrid CATT1)
Hybrid CATT1: Hybrid Closed Loop Insulin Pumps With Cadisegliatin as Adjunctive Treatment in Patients With Type 1 Diabetes A Phase 2a Double Blind Randomized Cross-Over Study
TTP399-206 is a Phase 2a multicenter double blind cross over randomized study of cadisegliatin in participants with T1D using hybrid closed loop systems to manage their diabetes. Participants using a hybrid closed loop insulin pump to manage their diabetes will be randomized to either receive blinded cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment or placebo QD along with their insulin treatment. The trial begins with a screening period of up to 2 weeks, followed by a device training and insulin adjustment period of 1-2 weeks leading into the first double-blind treatment period of 6 weeks. There will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participants will cross-over to the treatment that they did not receive in the first treatment period.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
TTP399-206 is a 20 week, Phase 2a trial designed to evaluate efficacy and safety of cadisegliatin in participants with T1D who are using hybrid closed loop (HCL) systems to manage their condition to gather preliminary data to understand how cadisegliatin performs in an HCL setting.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Meaghan Marnell
- Número de telefone: (336) 888-0435
- E-mail: clinicaltrials@vtvtherapeutics.com
Locais de estudo
-
-
California
-
Modesto, California, Estados Unidos, 95355
- Recrutamento
- Paradigm Clinical Research -Modesto
-
Investigador principal:
- Gopika Gangupantula, MD
-
San Diego, California, Estados Unidos, 92108
- Recrutamento
- Paradigm Clinical Research Centers, LLC
-
Investigador principal:
- Schafer Boeder, MD
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Recrutamento
- Barbara Davis Center for Diabetes
-
Investigador principal:
- Halis Kaan Akturk, MD
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30318
- Recrutamento
- Atlanta Diabetes Associates
-
Investigador principal:
- Bruce W Bode, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27514
- Recrutamento
- UNC Eastowne Medical Office Building
-
Investigador principal:
- Klara Klein, MD, PhD
-
-
Texas
-
Austin, Texas, Estados Unidos, 78731
- Recrutamento
- Texas Diabetes & Endocrinology, P.A.
-
Investigador principal:
- Thomas Blevins, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Key Inclusion Criteria:
- Participants >= 18 years of age
- Fasting C-peptide levels <0.6 ng/ml
- Average TIR < 70% recorded on their personal CGM data collected over the past 7 days prior to Visit 1
- Currently on a hybrid closed loop device for at least 3 months and willing to stay on the same model of pump device for study duration
- Willing to wear a study provided CGM for study duration
- Total bilirubin ≤2×ULN, ALT and AST ≤3×ULN
Key Exclusion Criteria:
- Have Type 2 Diabetes Mellitus (DM), monogenic diabetes, maturity-onset diabetes, other unusual or rare forms of DM, or diabetes resulting from a secondary disease.
- Have been hospitalized for DKA within 3 months
- Have uncontrolled hypothyroidism or hyperthyroidism
- Have QTcF interval > 450 msec for males or > 470 msec for females
- Have a personal or family history of long QT syndrome, Torsades de pointes, or other complex ventricular arrhythmias
- Have persistent, uncontrolled hypertension
- Have clinically significant cardiovascular or cerebrovascular disease
- Have proliferative retinopathy or maculopathy requiring acute treatment
- Have a serious concomitant systemic disorder including but not limited to HIV or active Hep B or Hep C
- Have been diagnosed and/or treated for malignancy within 3 years
- Have used any of the following medications within the specified time periods: any non-insulin anti-diabetic therapies (e.g.SGLT-2 inhibitors, GLP-1 receptor agonists, metformin, sulfonylureas, DPP-4 inhibitors, pramlintide, a-glucosidase inhibitors, or glucose dependent insulinotropic polypeptide agonists) within 30 days, antipsychotic medications (e.g. olanzapine, risperidone, clozapine, quetiapine, and haloperidol) within 30 days, systemic corticosteroids for ≥7 days for a temporary medical condition within 30 days,
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Cadisegliatin 800 mg QD, then Placebo
If a participant is randomized to receive cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment in the first double-blind treatment period of 6 weeks, there will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participant will cross-over to the placebo QD along with their insulin treatment |
Cadisegliatin is an orally bioavailable small-molecule glucokinase activator, adjunctive therapy to insulin
Outros nomes:
Placebo (insulin alone) |
|
Experimental: Placebo, then Cadisegliatin 800 mg QD
If a participant is randomized to receive placebo QD along with their insulin treatment in the first double-blind treatment period of 6 weeks, there will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participant will cross-over to the cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment |
Cadisegliatin is an orally bioavailable small-molecule glucokinase activator, adjunctive therapy to insulin
Outros nomes:
Placebo (insulin alone) |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
To assess the change in Time in Range (TIR)
Prazo: last 2 weeks of the two 6-week treatment periods
|
Time in Range (TIR) based on study CGM in participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo |
last 2 weeks of the two 6-week treatment periods
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
CGM-based metric for glycemic control
Prazo: last 2 weeks of each treatment period
|
Time In Tight Range (TITR) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
Prazo: last 2 weeks of each treatment period
|
Time Above Range (TAR) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
Prazo: last 2 weeks of each treatment period
|
Time Below Range (TBR) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
Prazo: last 2 weeks of each treatment period
|
Glucose Management Indicator (GMI) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
Prazo: last 2 weeks of each treatment period
|
Glucose variability (GV) |
last 2 weeks of each treatment period
|
|
CGM-based metric for glycemic control
Prazo: last 2 weeks of each treatment period
|
Time in Range (TIR) > 70% |
last 2 weeks of each treatment period
|
|
Change in glucose control after standardized mixed meal tolerance test (MMTT)
Prazo: 12 weeks
|
Glucose Peak Plasma Concentration (Cmax) based on study CGM after standardized mixed meal tolerance test (MMTT) |
12 weeks
|
|
Change in glucose control after standardized mixed meal tolerance test (MMTT)
Prazo: 12 weeks
|
Glucose Area under the plasma concentration versus time curve (AUC) based on study CGM after standardized mixed meal tolerance test (MMTT) |
12 weeks
|
|
To assess the change in Level 1, Level 2 , and Level 3 hypoglycemic incidence
Prazo: 12 weeks
|
Number of events of Level 1 and Level 2 hypoglycemia as determined by CGM and Level 3 hypoglycemic events in participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo |
12 weeks
|
|
Assess incidence of Serious Adverse Events (SAEs)
Prazo: 14 weeks
|
Number of Serious Adverse Events (SAEs) |
14 weeks
|
|
Assess incidence of Treatment Emergent Adverse Events (TEAEs)
Prazo: 14 weeks
|
Number of treatment emergent adverse events (TEAEs) |
14 weeks
|
|
Assess incidence of Treatment Emergent Adverse Events (TEAEs) leading to discontinuation
Prazo: 14 weeks
|
Number of treatment emergent adverse events (TEAEs) leading to discontinuation of study drug |
14 weeks
|
|
Assess incidence of Adverse Events of Special Interest (AESIs)
Prazo: 14 weeks
|
Number of adverse events of special interest (AESIs) |
14 weeks
|
|
Change from baseline in average daily total insulin dose
Prazo: last week of the two 6-week treatment periods
|
Change from baseline in average daily total insulin dose in units (IU) based on manual entry in eDiary records from participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo |
last week of the two 6-week treatment periods
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Maria Alba, MD, vTv Therapeutics LLC
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- TTP399-206
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .